Paper7907950
Pharmacokinetics and metabolism of Taxotere (docetaxel).
Bruno R and 1 other. Cancer Surv, 1993. Cited by 84 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetics and metabolism of Taxotere (docetaxel). Papers, record 7907950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7907950
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Phytogenic | Major topic |
| Neoplasms | Major topic |
| Paclitaxel | Major topic |
| Taxoids | Major topic |
| Clinical Trials, Phase I as Topic | |
| Clinical Trials, Phase II as Topic | |
| Docetaxel | |
| Humans |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882832 | Neoadjuvant Advantage, Adjuvant Challenge: Clinical Evidence and Hypothetical Biological Mechanisms Behind Divergent Tolerability. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882832 | PubMed |
| 38554227 | Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions. | J Pharmacokinet Pharmacodyn | 2024 | https://conductscience.org/library/papers/38554227 | PubMed |
| 38093346 | Dynamic altruistic cooperation within breast tumors. | Mol Cancer | 2023 | https://conductscience.org/library/papers/38093346 | PubMed |
| 32969563 | Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. | BJU Int | 2021 | https://conductscience.org/library/papers/32969563 | PubMed |
| 29977602 | Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. | NPJ Syst Biol Appl | 2018 | https://conductscience.org/library/papers/29977602 | PubMed |
| 25728850 | Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. | Cancer Sci | 2015 | https://conductscience.org/library/papers/25728850 | PubMed |
| 24639951 | In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. | Front Oncol | 2014 | https://conductscience.org/library/papers/24639951 | PubMed |
| 24442774 | Efficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxel. | AAPS PharmSciTech | 2014 | https://conductscience.org/library/papers/24442774 | PubMed |
| 23616082 | Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. | J Pharmacokinet Pharmacodyn | 2013 | https://conductscience.org/library/papers/23616082 | PubMed |
| 21692829 | Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report. | Br J Clin Pharmacol | 2011 | https://conductscience.org/library/papers/21692829 | PubMed |
| 20959830 | Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. | Br J Cancer | 2010 | https://conductscience.org/library/papers/20959830 | PubMed |
| 20399458 | A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. | J Urol | 2010 | https://conductscience.org/library/papers/20399458 | PubMed |
| 18611060 | Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. | Clin Pharmacokinet | 2008 | https://conductscience.org/library/papers/18611060 | PubMed |
| 15122076 | Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC). | Invest New Drugs | 2004 | https://conductscience.org/library/papers/15122076 | PubMed |
| 10933515 | Docetaxel: a review of its use in non-small cell lung cancer. | Drugs Aging | 2000 | https://conductscience.org/library/papers/10933515 | PubMed |
| 10883663 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. | Br J Cancer | 2000 | https://conductscience.org/library/papers/10883663 | PubMed |
| 10803455 | Adaptive control methods for the dose individualisation of anticancer agents. | Clin Pharmacokinet | 2000 | https://conductscience.org/library/papers/10803455 | PubMed |
| 10776837 | Docetaxel: an update of its use in advanced breast cancer. | Drugs | 2000 | https://conductscience.org/library/papers/10776837 | PubMed |
| 9878990 | Practical treatment guide for dose individualisation in cancer chemotherapy. | Drugs | 1998 | https://conductscience.org/library/papers/9878990 | PubMed |
| 8913835 | Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. | Invest New Drugs | 1996 | https://conductscience.org/library/papers/8913835 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7907950
GET https://conductscience.org/api/papers/v1/7907950/cited_by?page=2